448 related articles for article (PubMed ID: 19133215)
1. [Viral entry as therapeutic target. Current situation of entry inhibitors].
Arenzana-Seisdedos F
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
[TBL] [Abstract][Full Text] [Related]
2. [Mechanisms of resistance and failure of treatment with maraviroc].
Delgado R
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():28-33. PubMed ID: 19133219
[TBL] [Abstract][Full Text] [Related]
3. [Conclusions and perspectives. Maraviroc].
Alcamí J
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():49-54. PubMed ID: 19133222
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics, interactions and mechanism of action of maraviroc].
Soriano V; Poveda E
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():12-6. PubMed ID: 19133216
[TBL] [Abstract][Full Text] [Related]
5. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Panos G; Watson DC
Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
[TBL] [Abstract][Full Text] [Related]
6. [Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker].
Arribas López JR
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():23-7. PubMed ID: 19133218
[TBL] [Abstract][Full Text] [Related]
7. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
[TBL] [Abstract][Full Text] [Related]
8. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
[TBL] [Abstract][Full Text] [Related]
9. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
10. HIV entry and fusion inhibitors.
Chantry D
Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
[TBL] [Abstract][Full Text] [Related]
11. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.
Tan Q; Zhu Y; Li J; Chen Z; Han GW; Kufareva I; Li T; Ma L; Fenalti G; Li J; Zhang W; Xie X; Yang H; Jiang H; Cherezov V; Liu H; Stevens RC; Zhao Q; Wu B
Science; 2013 Sep; 341(6152):1387-90. PubMed ID: 24030490
[TBL] [Abstract][Full Text] [Related]
12. [Maraviroc efficacy in clinical studies on the development of the molecule].
Moreno S; Hernández B; Gutiérrez C; Delsol E
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():17-22. PubMed ID: 19133217
[TBL] [Abstract][Full Text] [Related]
13. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
14. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of viral entry.
Melby T; Westby M
Handb Exp Pharmacol; 2009; (189):177-202. PubMed ID: 19048201
[TBL] [Abstract][Full Text] [Related]
16. C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors.
Hu Q; Huang X; Shattock RJ
J Gen Virol; 2010 Dec; 91(Pt 12):2965-73. PubMed ID: 20810746
[TBL] [Abstract][Full Text] [Related]
17. HIV entry inhibitors: progress in development and application.
Lai WH; Huang L; Chen CH
Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
[TBL] [Abstract][Full Text] [Related]
18. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
[TBL] [Abstract][Full Text] [Related]
19. An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.
Bozek K; Eckhardt M; Sierra S; Anders M; Kaiser R; Kräusslich HG; Müller B; Lengauer T
Retrovirology; 2012 Jul; 9():60. PubMed ID: 22830600
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
Hunt JS; Romanelli F
Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
